文献速递脊柱关节炎

欧洲真实世界研究中certolizumab pegol治疗中轴型脊柱关节炎12个月的有效性与安全性

Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

CIMAX研究是一项欧洲非干预性多中心前瞻性研究,观察certolizumab pegol(CZP)治疗中轴型脊柱关节炎(axSpA)52周的真实世界疗效与安全性。672例患者接受至少1剂CZP,其中564例纳入有效性分析,第52周BASDAI平均变化为-2.9(n=439),放射学axSpA为-2.9(n=301),非放射学axSpA为-2.8(n=137),均P<0.0001。37.9%(255/672)患者发生不良事件,1.8%(12/672)发生至少1次严重不良事件,未发现新的安全性问题。

要点

  • 真实世界中CZP治疗axSpA第52周BASDAI平均改善-2.9,与随机临床试验结果相似。
  • 放射学与非放射学axSpA亚组的BASDAI改善分别为-2.9和-2.8。
  • 37.9%患者报告不良事件,1.8%报告严重不良事件,无新安全性信号。

核心结论

  • 真实临床实践中CZP治疗axSpA一年后的症状和体征改善与既往随机临床试验相似,未发现新的安全性问题。

研究设计与样本

  • CIMAX(NCT02354105)为欧洲非干预性多中心前瞻性研究,观察CZP治疗12个月的真实世界axSpA队列。
  • 672例接受至少1剂CZP的患者纳入安全性随访,其中564例有基线及至少1次基线后BASDAI评估者纳入有效性分析。

主要发现

  • 总体axSpA、放射学axSpA和非放射学axSpA的基线BASDAI均值均为6.1。
  • 第52周总体BASDAI平均(标准差)变化为-2.9(2.3;n=439),放射学axSpA为-2.9(2.2;n=301),非放射学axSpA为-2.8(2.4;n=137),均P<0.0001。
  • 其他axSpA疾病指标也观察到类似改善。
  • 37.9%(255/672)患者发生不良事件,1.8%(12/672)发生至少1次严重不良事件。

临床怎么用

  • 真实世界数据支持CZP用于放射学和非放射学axSpA患者,疗效与随机对照试验一致。
  • 治疗期间需关注不良事件,严重不良事件发生率较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The efficacy and safety of certolizumab pegol (CZP), an Fc-free, PEGylated anti-TNF, in axial spondyloarthritis (axSpA) has been established in clinical trial settings. We report CZP effectiveness and safety in European clinical practice in patients with axSpA, including radiographic (r-) and non-radiographic (nr-) axSpA. METHODS: CIMAX (NCT02354105), a European non-interventional multicentre prospective study, observed CZP treatment response and safety over 12 months in a real-world axSpA cohort. The primary outcome was change from baseline in BASDAI to week 52, with additional outcomes pertaining to effectiveness and safety. Patients who received ≥1 dose CZP were followed up for adverse events, and those with baseline and ≥1 post-baseline BASDAI assessment were included in effectiveness analyses. RESULTS: A total of 672 patients (r-axSpA: 469; nr-axSpA: 201; unconfirmed diagnosis: 2) from 101 sites received ≥1 dose of CZP, of whom 564 (r-axSpA: 384; nr-axSpA: 179; unconfirmed: 1) were included in the effectiveness analyses. The mean baseline BASDAI was 6.1 in the overall axSpA population and r-axSpA and nr-axSpA subpopulations. At week 52, the mean (s.d.) change in BASDAI was -2.9 (2.3; n = 439); for r-axSpA and nr-axSpA, it was -2.9 (2.2; n = 301) and -2.8 (2.4; n = 137), respectively (P <0.0001 for all). Similar improvements were seen across other axSpA disease measures. In total, 37.9% (255/672) patients experienced adverse events, and 1.8% (12/672) experienced ≥1 serious adverse events. CONCLUSION: Improvements observed in signs and symptoms of axSpA following one year of CZP treatment in real-world clinical practice were similar to those from previous randomized clinical trials, with no new safety concerns.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Baraliakos X, Witte T, De Clerck L, et al. Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe. Rheumatology (Oxford). 2021. PMID: 32584415. doi:10.1093/rheumatology/keaa181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。